CY1116801T1 - Χρηση εστερων καρβοξυλικης αμιδοξιμης και εστερων καρβοξυλικης ν-υδροξυγουανιδινης για την παρασκευη προφαρμακων - Google Patents

Χρηση εστερων καρβοξυλικης αμιδοξιμης και εστερων καρβοξυλικης ν-υδροξυγουανιδινης για την παρασκευη προφαρμακων

Info

Publication number
CY1116801T1
CY1116801T1 CY20151100936T CY151100936T CY1116801T1 CY 1116801 T1 CY1116801 T1 CY 1116801T1 CY 20151100936 T CY20151100936 T CY 20151100936T CY 151100936 T CY151100936 T CY 151100936T CY 1116801 T1 CY1116801 T1 CY 1116801T1
Authority
CY
Cyprus
Prior art keywords
carboxylic acid
preparations
preparation
hydroxyguanidine
hydroxyamidine
Prior art date
Application number
CY20151100936T
Other languages
English (en)
Inventor
Bernd Clement
Christiane Reeh
Helen Hungeling
Original Assignee
Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg filed Critical Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg
Publication of CY1116801T1 publication Critical patent/CY1116801T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/62—Oximes having oxygen atoms of oxyimino groups esterified
    • C07C251/64—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids
    • C07C251/66—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids with the esterifying carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μία μέθοδο για τη βελτίωση της βιοδιαθεσιμότητας και της δυνατότητας διαπέρασης του φράγματος-αίματος-εγκεφάλου σε φαρμακευτικές ουσίες οι οποίες έχουν τουλάχιστον μία ή περισσότερες από τις δραστικές ομάδες αμιδίνη, γουανιδίνη, Ν-υδροξυαμιδίνη (αμιδοξίμη) ή αντίστοιχα Ν-υδροξυγουανιδίνη και φάρμακα τα οποία περιέχουν αντίστοιχα τροποποιημένες φαρμακευτικές ουσίες.
CY20151100936T 2008-02-01 2015-10-20 Χρηση εστερων καρβοξυλικης αμιδοξιμης και εστερων καρβοξυλικης ν-υδροξυγουανιδινης για την παρασκευη προφαρμακων CY1116801T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008007381A DE102008007381A1 (de) 2008-02-01 2008-02-01 Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
EP09705303.7A EP2249821B1 (de) 2008-02-01 2009-02-02 Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs

Publications (1)

Publication Number Publication Date
CY1116801T1 true CY1116801T1 (el) 2017-03-15

Family

ID=40532565

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100936T CY1116801T1 (el) 2008-02-01 2015-10-20 Χρηση εστερων καρβοξυλικης αμιδοξιμης και εστερων καρβοξυλικης ν-υδροξυγουανιδινης για την παρασκευη προφαρμακων

Country Status (21)

Country Link
US (2) US20110028756A1 (el)
EP (3) EP2732816A1 (el)
JP (2) JP2011510956A (el)
KR (1) KR20100110875A (el)
CN (1) CN101951897B (el)
AU (1) AU2009209560B2 (el)
BR (1) BRPI0906569A2 (el)
CA (1) CA2713784C (el)
CY (1) CY1116801T1 (el)
DE (1) DE102008007381A1 (el)
DK (1) DK2249821T3 (el)
ES (1) ES2547117T3 (el)
HK (1) HK1153144A1 (el)
HR (1) HRP20150961T1 (el)
HU (1) HUE026276T2 (el)
IL (1) IL207286A0 (el)
PL (1) PL2249821T3 (el)
PT (1) PT2249821E (el)
SI (1) SI2249821T1 (el)
WO (1) WO2009095499A1 (el)
ZA (1) ZA201004767B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
EP2550966B1 (de) * 2011-07-25 2016-10-19 Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG Dabigatran-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel
LT2550963T (lt) 2011-07-25 2017-02-27 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Pentamidino-amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų naudojimas kaip vaistų
ES2416004B1 (es) * 2012-01-24 2014-01-28 Investigaciones Farmaceuticas Y Veterinarias, S.L. Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales.
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
US9375411B2 (en) * 2012-12-21 2016-06-28 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
CN106831611B (zh) * 2017-01-23 2019-06-21 北京化工大学 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JP2001031586A (ja) * 1999-07-14 2001-02-06 Sunstar Inc 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物
EP1294405A2 (en) 2000-06-14 2003-03-26 Corixa Corporation Prodrug compounds cleavable by thimet oligopeptidase
ES2364452T3 (es) * 2001-06-11 2011-09-02 Medarex, Inc. Método para diseñar compuestos profármacos activados por cd10.
MXPA04003169A (es) * 2001-10-03 2004-07-08 Pharmacia Corp Profarmacos de compuestos policiclicos sustituidos utiles para inhibicion selectiva de la cascada de coagulacion.
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
JPWO2005049636A1 (ja) * 2003-11-21 2007-06-07 日本電気株式会社 タンパク質の分析方法
CA2572161C (en) 2004-06-30 2012-10-02 Toyama Chemical Co., Ltd. Novel arylamidine derivative, salt thereof, and antifungal containing these
DE102006034256A1 (de) * 2006-07-21 2008-01-31 Christian-Albrechts-Universität Zu Kiel Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten

Also Published As

Publication number Publication date
CA2713784A1 (en) 2009-08-06
PT2249821E (pt) 2015-10-13
BRPI0906569A2 (pt) 2015-07-07
KR20100110875A (ko) 2010-10-13
DE102008007381A1 (de) 2009-08-13
US9353047B2 (en) 2016-05-31
WO2009095499A1 (de) 2009-08-06
AU2009209560A1 (en) 2009-08-06
SI2249821T1 (sl) 2015-12-31
CN101951897B (zh) 2016-01-20
US20140350293A1 (en) 2014-11-27
EP2249821B1 (de) 2015-07-29
EP2249821A1 (de) 2010-11-17
ZA201004767B (en) 2011-04-28
AU2009209560B2 (en) 2013-10-31
HK1153144A1 (zh) 2012-03-23
EP2732816A1 (de) 2014-05-21
DK2249821T3 (en) 2015-10-05
EP2985021A1 (de) 2016-02-17
CN101951897A (zh) 2011-01-19
IL207286A0 (en) 2010-12-30
US20110028756A1 (en) 2011-02-03
HRP20150961T1 (hr) 2015-11-06
ES2547117T3 (es) 2015-10-01
JP2011510956A (ja) 2011-04-07
JP2016193927A (ja) 2016-11-17
PL2249821T3 (pl) 2015-12-31
HUE026276T2 (en) 2016-06-28
CA2713784C (en) 2016-09-27

Similar Documents

Publication Publication Date Title
CY1116801T1 (el) Χρηση εστερων καρβοξυλικης αμιδοξιμης και εστερων καρβοξυλικης ν-υδροξυγουανιδινης για την παρασκευη προφαρμακων
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
CY1113177T1 (el) Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων
HRP20161577T1 (hr) Inhibitori replikacije virusa gripe
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
AR072842A1 (es) Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico
CO6511251A2 (es) Compuestos quimicos
CY1113141T1 (el) Απαραβιαστες φαρμακοτεχνικες μορφες δοσολογιας απο του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
CY1108220T1 (el) Κρυσταλλικη μορφη γd της υδροχλωρικης ιβαβραδινης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
CY1116361T1 (el) Ετεροαρωματικα αρυλο τριαζολικα παραγωγα ως αναστολεις pde10a ενζυμου
CY1112173T1 (el) Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας
CY1114791T1 (el) Πιμοβενδανη για χρηση στη θεραπεια της υπερτροφικης μυοκαρδιοπαθειας σε γατες
SG10201807904RA (en) Mitochondria-Targeted Dicarbonyl Sequestering Compounds
CY1112764T1 (el) Φαρμακευτικο προϊον για ενεση
CY1118585T1 (el) Ενωση βενζοθειαζολονης
CY1113999T1 (el) Σταθερο ετοιμο προς χρηση ενεσιμο σκευασμα παρακεταμολης
CY1118302T1 (el) Λωριδα χαρτιου για τον καθορισμο των ελαχιστων ανασταλτικων συγκεντρωσεων αντιβιοτικων
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
WO2009095503A3 (de) Aminosäurederivate als arzneistoffe
EA200800150A1 (ru) Состав с пролонгированным высвобождением действующих начал лекарственного средства
ATE529099T1 (de) Pharmazeutische einzeldosisform
TH117353A (th) ไซคลิคกัวนิดีนใช้เป็นสารกั้น ENaC
TH158374A (th) สารยับยั้งมาโครไซคลิกของไวรัส flaviviridae ไวรัส